Dual angiotensin II and endothelin receptor antagonists.
Endothelin and angiotensin II are potent vasoconstrictor substances that also can exert proliferative and proinflammatory effects. Dysregulation of these systems can induce or mediate endothelial dysfunction and organ damage in systemic hypertension. Dual-acting angiotensin II and endothelin receptor blockers have been shown to reduce systemic blood pressure in animal models and in hypertensive patients. Preliminary data in smaller human studies have shown that these agents are safe and well tolerated. Larger randomized trials evaluating the efficacy and safety of these agents are underway and show potential as a new class of antihypertensives.
Palaniswamy
Chandrasekar
C
Department of Medicine, New York Medical College, Valhalla, USA. drpchandrasekar@gmail.com
Selvaraj
Dhana R
DR
Palaniappan
Dhamodaran
D
D057911:Angiotensin Receptor Antagonists / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D000818:Animals; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D001794:Blood Pressure / Q000187:drug effects; D065128:Endothelin Receptor Antagonists; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000453:epidemiology / Q000503:physiopathology; D017466:Receptors, Endothelin / Q000378:metabolism; D014662:Vasoconstrictor Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use
D057911:Angiotensin Receptor Antagonists; D000959:Antihypertensive Agents; D065128:Endothelin Receptor Antagonists; D017466:Receptors, Endothelin; D014662:Vasoconstrictor Agents